By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – China Medical Technologies today announced that its PCR-based KRAS assay has been approved in China as a companion diagnostic for an undisclosed drug targeting colorectal cancer.

The assay was approved by China's State Food and Drug Administration for the detection of specific mutations in the KRAS gene. According to China Med Tech, about 40 percent of colorectal cancer patients have mutations to the gene that may render them non-responsive to the targeted drug.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.